Table 1.

List of clinical trials related to the treatment of aggressive PAs (https://clinicaltrials.gov [26] (accessed on 6 November 2021)).

Mechanism of Action	Intervention(s)	Trial Identifier	Study Title	Recruitment Status	Condition	Phase	Number of Enrolled Patients	Study Type	Primary Purpose
checkpoint inhibition	Ipilimumab, Nivolumab	NCT04042753	Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors	recruiting	pituitary tumor	II	21 *	clinical trial	treatment
checkpoint inhibition	Ipilimumab, Nivolumab	NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	recruiting	pituitary carcinoma	II	818 *	clinical trial	treatment
checkpoint inhibition	Pembrolizumab	NCT02721732	Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic	active, not recruiting	pituitary tumor	II	202	clinical trial	treatment
dopamine agonist treatment	Cabergoline	NCT03271918	Cabergoline in Nonfunctioning Pituitary Adenomas (NFPA)	completed	NFPA	III	140	clinical trial	treatment
dopamine agonist treatment	Cabergoline	NCT02288962	Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas	recruiting	NFPA	III	60 *	clinical trial	treatment
dopamine agonist treatment	Cabergoline	NCT00889525	Study of Cabergoline in Treatment of Corticotroph Pituitary Adenoma	completed	Cushing’s disease	III	unknown	clinical trial	treatment
epidermal growth factor receptor (EGFR) inhibition	Lapatinib	NCT00939523	Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy	completed	pituitary tumor	II	9	clinical trial	treatment
epidermal growth factor receptor (EGFR) inhibition	Gefitinib	NCT02484755	Targeted Therapy With Gefitinib in Patients With USP8 **-mutated Cushing’s Disease	unknown	Cushing’s disease	II	6 *	clinical trial	treatment
interference with deoxyribonucleid acid (DNA) replication	Temozolomide, Radiotherapy	NCT04244708	The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas	not yet recruiting	pituitary tumor	II	150 *	clinical trial	treatment
interference with deoxyribonucleid acid (DNA) replication	Temozolomide, Fluorouracil	NCT03930771	Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas	terminated	pituitary tumor	II	1	clinical trial	treatment

* estimated enrollment; ** ubiquitin specific peptidase 8.